Principal Investigators //
- Corey Hill Allen, PhD >
- Nathaniel Anderson, PhD >
- Felicha Candelaria-Cook, PhD >
- Arvind Caprihan, PhD >
- Bethany Edwards, Ph.D. >
- Aparna Gullapalli, PhD >
- Carla Harenski, PhD >
- Jon Houck, Ph.D. >
- Kent A. Kiehl, PhD >
- J. Michael Maurer, PhD >
- Andrew R. Mayer, PhD >
- John Phillips, MD >
- Sephira Ryman, PhD, MS
- Julia M. Stephen, PhD >
- Andrei Vakhtin, Ph.D. >
- Claire E. Wilcox, MD >
- Vadim Zotev, Ph.D. >
Sephira Ryman, PhD, MS
Associate Professor
Dr. Sephira Ryman is an Associate Professor and Clinical Neuropsychologist. She studied psychology and neuroscience at Wellesley College. She completed her neuropsychology training at the University of New Mexico (PhD), University of California, Los Angeles (Internship), and Stanford Medical Center (Fellowship). Her research lab is interested in understanding microbiome, cerebrovascular, and glymphatic mechanisms and developing novel treatments for neurodegenerative conditions such as Parkinson's disease, Dementia with Lewy bodies, and Alzheimer's disease. The lab is currently supported by NIH R03 and R01 mechanisms to pursue these aims, though it collaborates on numerous projects examining biomarkers and neuropsychiatric functioning across Traumatic Brain Injury, Depression, Alzheimer’s disease, and Vascular Cognitive Impairment. Dr. Ryman currently serves as the Associate Director of the Clinical Core for the exploratory New Mexico Exploratory Alzheimer's Disease Research Center. She is originally from New Mexico and thrilled to partner with communities to learn more about how our research can improve the lives of individuals impacted by neurological and psychiatric conditions.
For more information about specific studies, to volunteer for a study, or meet Dr. Ryman's research team, visit links on the left hand side of the page or email agingstudy@mrn.org. You may also contact us at: (505)-803-5499. Also read more about our work here: https://sites.google.com/mrn.org/gracelab/home
Email Dr. Ryman BG Memory Chapter
Selected Publications //
- Amplitude-determined seizure-threshold, electric field modeling, and electroconvulsive therapy antidepressant and cognitive >
- Cognition at Each Stage of Lewy Body Disease with Co-occurring Alzheimer’s Disease Pathology >
- Dopaminergic medication normalizes aberrant cognitive control circuit signalling in Parkinson’s disease >
- Microbiome-gut-brain dysfunction in prodromal and symptomatic Lewy body diseases >
- Illusory Responses across the Lewy Body Disease Spectrum >
- Longitudinal hippocampal subfields, CSF biomarkers, and cognition in patients with Parkinson disease >
- Reduced and Delayed Cerebrovascular Reactivity in Patients with Parkinson’s Disease >
- Multifaceted neural and vascular pathologies after pediatric mild traumatic brain injury >
- Comparison of automated and manual quantification methods for neuromelanin-sensitive MRI in Parkinson’s disease >
- Latent brain state dynamics and cognitive flexibility in older adults >
- MRI biomarkers of motor and non-motor symptoms in Parkinson’s disease >
- Fronto-Parietal gray matter and white matter efficiency differentially predict intelligence in males and females >
- Functional Brain Networks Contributing to the Parieto-Frontal Integration Theory of >
- Look Hear! The Prefrontal Cortex is Stratified by Modality of Sensory Input During Multisensory Cognitive Control >
Cognitive and Psychiatric Functioning in Aging
MRI biomarkers have been studied in individual neurodegenerative diseases, but there have been minimal amounts of research examining how MRI biomarkers relate to cognitive and psychiatric dysfunction accross neurodegenerative conditions. This study will examine, longitudinally and observationally, individuals diagnosed with neurodegenerative conditions and how those measures relate to cognitive and psychiatric functioning and whether those measures can predict functional outcomes over time. This research ultimately aims to facilitate earlier detection and improve treatments for neurodegenerative conditions. A significant gain in understanding the utility of MRI biomarkers to identify the presence and progression in neuropathological processes across neurodegenerative conditions is expected over the course of this study.
For more information feel free to email agingstudy@mrn.org or contact us at: (505)-803-5499
